NexImmune, Inc.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Craig R. Jalbert
- Full Time Employees
- 6
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- Address
- 9119 Gaither Road Gaithersburg MD United States of America 20877
- IPO Date
- Feb 12, 2021
- CIK
- 0001538210
- Website
- neximmune.com
- Similar Companies
- Business
- NexImmune, Inc. (NEXI) is a clinical-stage biotechnology company that develops antigen-directed immunotherapies using its proprietary Artificial Immune Modulation (AIM) nanoparticle technology platform to orchestrate targeted T cell-mediated immune responses for cancer, autoimmune disorders, and infectious diseases. Founded in 2011 and headquartered in Gaithersburg, Maryland, the company employs AIM technology, originally licensed from Johns Hopkins University, across two primary modalities: AIM Injectable (AIM INJ) for off-the-shelf direct injection or infusion to activate, tolerize, or delete antigen-specific T cells without ex vivo manufacturing; and AIM Adoptive Cell Therapy (AIM ACT) for engineered T cell products. Its pipeline includes the NEXI-100 series (preclinical, injectable AIM nanoparticles for hematologic malignancies and solid tumors); NEXI-200 series (preclinical, autoimmune diseases); NEXI-300 series (preclinical, infectious diseases); NEXI-001 (Phase 1/2, donor-derived T cells for relapsed/refractory acute myeloid leukemia or myelodysplastic syndromes post-allogeneic hematopoietic stem cell transplant); NEXI-002 (Phase 1/2 paused, patient-derived T cells for relapsed/refractory multiple myeloma after at least three prior lines of therapy); NEXI-003 (IND cleared, patient-derived T cells for second-line HPV-associated malignancies post-checkpoint inhibitors or platinum-based chemotherapy); and NEXI-004 (preclinical, patient-derived stem cells for EBV-associated diseases). NexImmune operates primarily in the United States, targeting oncology, autoimmune, and infectious disease markets with a lean workforce of approximately six employees under CEO Craig Jalbert. Recent developments include a $23 million funding round from investors such as ArrowMark Colorado Holdings LLC and Piedmont Capital Partners LLC; a $3.67 million registered direct offering in February 2024 priced at-the-market under Nasdaq rules with concurrent warrants; establishment of a research initiative with City of Hope focused on novel immunotherapeutic approaches for acute myeloid leukemia in late 2024; a 53% workforce reduction to streamline operations; pausing of AIM ACT program enrollments (NEXI-001, NEXI-002, NEXI-003) while seeking academic and industry partners for their advancement; and CEO Kristi Jones acquiring Series A Preferred Stock at nominal value, alongside ongoing preclinical progress in AIM INJ modalities.
Italian state investor CDP to raise stake in payments group Nexi
Italy's CDP against selling stake in Nexi, sources say
Graybug Vision (NASDAQ:GRAY) versus NexImmune (OTCMKTS:NEXI) Head-To-Head Review
NexImmune (NASDAQ:NEXI) Stock Price Up 2,169,900% – Here’s Why
NexImmune (NASDAQ:NEXI) versus Avenue Therapeutics (NASDAQ:ATXI) Head-To-Head Comparison
Critical Comparison: NexImmune (NASDAQ:NEXI) vs. IMV (OTCMKTS:IMVIQ)
Critical Survey: NexImmune (NASDAQ:NEXI) and Palatin Technologies (PINK:PTNT)
Head-To-Head Survey: NexImmune (NASDAQ:NEXI) versus Evotec (OTCMKTS:EVTCY)
eFFECTOR Therapeutics (NASDAQ:EFTR) & NexImmune (NASDAQ:NEXI) Critical Contrast
NEXI Stock Alert: NexImmune Delists From Nasdaq
What Is Going on With NexImmune (NEXI) Stock Today?
NexImmune Announces Closing of $3.67 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
NexImmune Announces $3.67 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
NexImmune (NEXI) Stock Rockets 80% Ahead of Potential Liquidation
Dear NEXI Stock Fans, Mark Your Calendars for Jan. 18
NEXI Stock Halted: What's Going on With NexImmune Shares Today?
Here's why penny stocks like GGE, NEXI, ALT, HCDI are pumping
Why Is NexImmune (NEXI) Stock Up 353% Today?
Why Is NexImmune (NEXI) Stock Down 10% Today?
NexImmune, Yale, and JDRF Extend Research Partnership for Type 1 Diabetes